,67 While FCRL5 and GPRC5D TCRTs have exhibited impressive anti-myeloma responses, especially in patients with prior BCMA therapy exposure, GPRC5Dlow/neg progressive disease has already been documented,52,62 and there is the potential for antigen escape through FCRL5 cleavage.67 The gene discussed is FCRL5; the disease is plasma cell myeloma.